Boston Scientific (BSX) Receives FDA Clearance for Asurys Fluid Management System

Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best Growth Stocks to Buy for the Next Decade. Boston Scientific Corporation (NYSE:BSX) is one of the best growth stocks to buy for the next decade. On March 30, Boston Scientific received FDA 510(k) clearance for its Asurys Fluid Management System, a new technology designed to manage irrigation and distention during endoscopic urologic procedures. The system is intended for use in ureteroscopy, cystoscopy, percutaneous nephrolithotomy/PCNL, and benign prostatic hyperplasia/BPH treatments.

By providing a single irrigation management solution, the device aims to streamline clinical workflows and assist in the diagnosis and treatment of conditions such as kidney stones. A primary feature of the Asurys System is its ability to regulate irrigation inflow to help maintain low intrarenal pressure/IRP while ensuring clear visualization. When paired with the LithoVue Elite Single-Use Digital Flexible Ureteroscope, the system can automatically respond to IRP data in real-time.

This capability is designed to help physicians minimize the risk of exceeding pre-set pressure settings, which is critical for avoiding post-operative complications like sepsis or renal damage. The system also integrates irrigation control directly onto the scope handle, allowing physicians to activate an on-demand flush feature to reposition stones without manual assistance.

Copyright: nimon / 123RF Stock Photo

Boston Scientific Corporation (NYSE:BSX) is a healthcare company,  incorporated in 1979, that specializes in medical devices for interventional medical specialties. The company’s segments include MedSurg and Cardiovascular.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.